Resmed Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Resmed Inc 's ROA in the fourth quarter of 2026?
Resmed Inc achieved a return on average assets (ROA) of 17.85 % in its fourth quarter of 2026, this is above RMD's average return on assets of 13.28%.
Resmed Inc s assets during the 12 months ending in the fourth quarter of 2026 are valued at $8 billion

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 55 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 267, from total ROA ranking in the third quarter of 2026 at 296.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	14.83 %	18.44 %	19.14 %	15.31 %	19.14 %
Y / Y Net Income Change	0.98 %	9.23 %	13.92 %	11.94 %	29.93 %
Net Income (TTM) in million	1,523	1,520	1,486	1,438	1,401
Return On Assets (TTM)	17.85 %	18.45 %	18.82 %	18.98 %	19.18 %
RMD's Total Ranking	# 267	# 296	# 264	# 266	# 268
Total Assets (TTM) in million	9,198	8,784	8,010	8,149	8,010
Seq. Total Assets Change	4.71 %	9.67 %	-1.7 %	1.73 %	8 %
Seq. Net Income Change	-3.84 %	1.56 %	12.64 %	-8.21 %	4.02 %

RMD's 5 Years Annual ROA >> Back to RMD Management Effectiveness >> Compare RMD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 12
Sector	# 56
Overall	# 272

Return On Assets Statistics
High	Average	Low
18.78 %	13.28 %	6.12 %
		(Jun 30 2013)

News about Resmed Inc Return on Assets ROA

ResMeds Forward-Thinking 2030 Strategy: A Robust Blueprint for Sustainable Growth and Shareholder Value

In a significant move aimed at securing its position as a leader in the healthcare sector, ResMed (NYSE: RMD, ASX: RMD) unveiled its ambitious 2030 Strategy during an Investor Day event held in New York City on September 30, 2024. This new initiative is designed to drive growth, enhance profitability, and maximize shareholder returns, reflecting ResMed s commitment to innovation and operational excellence.The backbone of ResMed’s 2030 Strategy lies in its comprehensive approach to product and technology innovation, which will serve as a catalyst for accelerated growth. The company has set an ambitious target to help more than 500 million people around the globe achieve their full health potential by the year 2030. This goal is underpinned by ResMed’s continuous investment in cutting-edge technologies designed to improve patient outcomes and streamline healthcare processes.

Financial Statements
Resmed Inc 's Assets	$ 9,198 million	RMD's Balance sheet
Resmed Inc 's Income	$ 383 million	Quarterly RMD's Income Statement
RMD's Income by Division		See RMD's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	21.96 %	19.14 %	1.45 %	33.46 %	7.87 %
Total Assets in million	9,769	8,010	6,723	6,627	4,966
Y / Y Net Income Change	8.75 %	37.2 %	13.75 %	15.15 %	64.26 %
Net Income in million	1,523	1,401	1,021	898	779
Annual Return On Assets	15.59 %	17.49 %	15.19 %	13.54 %	15.7 %

RMD's 5 Years Annual ROA >> Back to RMD Management Effectiveness >> Compare RMD ROA to its Competitors

Comment on RMD's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA deteriorated to 15.59 %, despite annual net income growth of 8.75 % to $1,523.29 million, from $1,400.72 million a year ago, as RMD's assets increase to $9,768.77 million, by 8.75 %.

More Return On Assets Ratios
RMD's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RMD's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RMD's Competitors
Subscribers only: Roa for Resmed Inc 's Suppliers
Subscribers only: Return On Assets for RMD's Customers

You may also want to know
RMD's Roi	RMD's Inventory Turnover Ratio	RMD's Growth Rates	RMD's Dividend Comparisons
	RMD's Profitability Ratios	RMD's Asset Turnover Ratio	RMD's Dividend Growth
RMD's Roe	RMD's Valuation Ratios	RMD's Financial Strength Ratios	RMD's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %

Date modified: 2026-09-08T15:22:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.